Postmenopause blood test checklist: markers to watch yearly

Postmenopause changes the meaning of routine blood work. The goal is no longer to “prove” menopause with FSH or chase a perfect estrogen number. If you have gone 12 months without a period, the more useful question is: which markers show whether cardiovascular risk, glucose control, bone context, thyroid status, inflammation, kidney function, liver function, and anemia risk are drifting?

That distinction matters. Postmenopause is associated with higher LDL cholesterol, more visceral fat, lower bone density, changing glucose tolerance, and a different symptom background than perimenopause. A generic annual panel can miss those patterns. A giant hormone panel can create noise without changing care.

This postmenopause blood test checklist is a doctor-discussion framework, not a prescription. Use it to prepare for an annual visit, decide which markers are worth repeating yearly, and separate useful tracking from testing that sounds precise but rarely answers a clinical question.

Key takeaways

The most useful yearly postmenopause review usually starts with lipids, glucose markers, CBC, comprehensive metabolic panel, blood pressure context, symptoms, medications, body composition, and bone-risk history.
Routine FSH, estradiol, progesterone, saliva hormones, or urine hormone metabolites are usually not needed to confirm postmenopause or tune standard menopause care.
Bone health needs a DEXA decision, not just calcium or vitamin D labs. USPSTF recommends osteoporosis screening for women 65 and older and for younger postmenopausal women with elevated fracture risk.
TSH, vitamin D, ferritin, hs-CRP, ApoB, Lp(a), B12, and fasting insulin can be useful, but the reason for ordering each test should be explicit.
A trend is more useful than one result. Repeat unexpected abnormalities under similar conditions before changing supplements, training, or medications.

What changes after menopause?

After the final menstrual period, estrogen stays lower and ovarian cycling no longer creates the same month-to-month hormone swings. That shift affects more than symptoms. The American Heart Association notes that the menopause transition is linked with adverse cardiometabolic changes, including increases in LDL cholesterol, metabolic-syndrome risk, abdominal fat, and vascular remodeling.

Those changes do not mean every postmenopausal woman needs a maximal longevity panel every year. They mean the annual review should be sharper. A useful checklist asks:

Is cardiovascular risk rising faster than expected?
Is glucose regulation changing even before diabetes thresholds?
Is bone loss being screened by risk and age, not guessed from serum calcium?
Is fatigue more consistent with anemia, thyroid disease, sleep disruption, medication effects, depression, or deconditioning?
Are kidney and liver markers stable enough for current medications and risk level?
Is inflammation persistent or just a temporary signal from illness, injury, dental work, or hard training?

For a broader midlife prevention map, start with the health checklist for women over 40. This article stays narrower: what to watch once you are already postmenopausal.

The practical yearly core panel

These are the markers most likely to be useful in a yearly postmenopause visit. Your clinician may adjust the list based on symptoms, medications, prior results, family history, surgical menopause, early menopause, cancer history, kidney disease, thyroid disease, osteoporosis, or cardiovascular risk.

Marker group	What to include	Why it matters after menopause	Typical cadence
Lipids and vascular risk	Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C; consider ApoB	LDL-C, abdominal fat, and metabolic-syndrome risk often rise through menopause	Every 1-3 years if stable; yearly if changing, high-risk, or treating
Glucose metabolism	Fasting glucose and HbA1c; consider fasting insulin or HOMA-IR	Insulin resistance and visceral-fat gain can move before diabetes is diagnosed	Yearly for many midlife adults; more often after abnormal results
CBC with differential	Hemoglobin, hematocrit, MCV, RDW, WBC, platelets	Screens anemia patterns, immune activation, medication effects, and nutritional clues	Yearly or risk-based
Comprehensive metabolic panel	Creatinine, eGFR, electrolytes, calcium, albumin, ALT, AST, alkaline phosphatase, bilirubin	Reviews kidney, liver, bone/liver enzyme context, calcium, hydration, and medication safety	Yearly or medication/risk-based
Thyroid first screen	TSH, with free T4 if abnormal or clinically indicated	Thyroid symptoms can overlap with menopause, but universal asymptomatic screening is not clearly proven	Symptom/risk-based; repeat if abnormal
Inflammation context	hs-CRP, interpreted cautiously	Persistent inflammation can signal cardiometabolic, dental, autoimmune, infection, or lifestyle burden	Optional; repeat unexpected highs
Nutrient and iron context	Ferritin, iron studies, B12, vitamin D when indicated	Useful for fatigue, anemia, neuropathy, bone risk, malabsorption, or dietary risk	Indication-based, not automatically yearly

The key is not to order every marker forever. The key is to know why each one is on the list and what decision would change if it moved.

1. Lipids: the cardiovascular marker set to stop ignoring

For many women, lipids are the most important postmenopause trend. A cholesterol panel includes LDL-C, HDL-C, triglycerides, total cholesterol, and often non-HDL cholesterol. ApoB adds particle-number context and can reveal risk when LDL-C looks less concerning than the number of atherogenic particles actually circulating.

Useful postmenopause questions:

Did LDL-C or non-HDL-C rise compared with the premenopause baseline?
Are triglycerides rising while HDL-C falls, suggesting metabolic-syndrome drift?
Is ApoB high enough to change the risk discussion?
Has Lp(a) been checked at least once, especially with family history of early cardiovascular disease?

CDC notes that most healthy adults should have cholesterol checked every 4 to 6 years, but postmenopause is often not a “set it and forget it” phase if prior values are changing. USPSTF statin guidance also makes risk factors such as dyslipidemia, diabetes, hypertension, and smoking central to decisions for adults 40 to 75.

For marker-specific interpretation, use the ApoB cardiovascular risk guide and the broader blood tests for longevity panel.

2. Glucose: HbA1c is useful, but not the whole story

Postmenopause can shift glucose handling through lower estrogen signaling, sleep disruption, visceral fat gain, lower muscle mass, and reduced activity after pain or poor recovery. Fasting glucose and HbA1c are mainstream, easy to repeat, and clinically familiar.

What to watch:

Fasting glucose trending toward 100 mg/dL (5.6 mmol/L)
HbA1c trending toward 5.7%
Triglycerides rising at the same time as waist circumference
Normal glucose with high fasting insulin, especially when waist, sleep, or energy is worsening

USPSTF recommends screening adults 35 to 70 who have overweight or obesity for prediabetes and type 2 diabetes. That recommendation is not menopause-specific, but it becomes especially relevant when postmenopause brings weight redistribution or higher cardiometabolic risk.

Fasting insulin is not required for routine diabetes screening, but it can be useful when the question is early insulin resistance rather than diagnosis. If your fasting glucose and HbA1c look “normal” but waist, triglycerides, or cravings are moving, compare this with fasting insulin as a longevity biomarker and HbA1c and aging.

3. CBC: do not normalize fatigue without checking the basics

A complete blood count is not glamorous, but it answers practical questions. Postmenopausal bleeding is never something to dismiss as a period. Iron-deficiency anemia after menopause needs a different level of attention than iron depletion during heavy perimenopausal cycles.

Useful CBC patterns:

Low hemoglobin or hematocrit: anemia pattern that deserves follow-up
High MCV: possible B12 or folate context, alcohol, liver disease, thyroid context, or medication effect
High RDW: variable red blood cell size, often useful beside iron, B12, inflammation, and chronic-disease context
High or low WBC: infection, inflammation, medication, immune, or marrow context
Platelet changes: inflammation, iron deficiency, liver/spleen context, or other clinical issues

If CBC is abnormal, the next step is rarely a single supplement guess. Ferritin, iron studies, B12, folate, reticulocyte count, kidney function, thyroid context, bleeding history, GI symptoms, medication review, and age-appropriate cancer screening may matter.

4. CMP: kidney, liver, calcium, albumin, and medication context

A comprehensive metabolic panel connects several postmenopause priorities:

Creatinine and eGFR: kidney filtration context, medication dosing, dehydration, blood pressure, diabetes, and age-related reserve
ALT, AST, alkaline phosphatase, bilirubin, and albumin: liver, metabolic, alcohol, medication, nutrition, and bone/liver enzyme context
Calcium: useful context, but not a bone-density test
Electrolytes: medication, hydration, kidney, adrenal, and blood pressure context

Do not overread a single mildly abnormal liver enzyme or eGFR estimate without context. Hard training, dehydration, supplements, alcohol, medications, muscle mass, lab variation, and recent illness can all move results. Repeat timing matters.

If ALT is normal but metabolic risk is rising, a standard panel can still miss fatty-liver risk. That is why a postmenopause checklist should connect CMP with waist, triglycerides, HbA1c, fasting insulin, blood pressure, and imaging decisions when appropriate.

5. Bone health: DEXA beats guessing from blood calcium

Serum calcium is not a screening test for osteoporosis. Many people with osteoporosis have normal blood calcium. Bone risk after menopause is about cumulative estrogen loss, age, fracture history, family history, body size, medications, smoking, alcohol, inflammatory disease, kidney disease, and fall risk.

USPSTF recommends osteoporosis screening to prevent fractures in women 65 and older. It also recommends screening postmenopausal women younger than 65 who have one or more risk factors and are at increased fracture risk by a clinical risk assessment.

Blood tests can support the bone conversation, but they do not replace DEXA:

Calcium, albumin, alkaline phosphatase, creatinine/eGFR, and sometimes phosphate or parathyroid hormone can clarify secondary causes.
Vitamin D testing can be useful in osteoporosis, malabsorption, certain medications, kidney disease, or prior deficiency.
Endocrine Society 2024 guidance argues against routine vitamin D testing in generally healthy adults for disease prevention, so the reason for testing should be specific.

If bone density is the main concern, read osteoporosis, bone aging, and DEXA before assuming a normal calcium result means bone risk is low.

6. Thyroid: test symptoms, risks, and prior results, not every vague complaint

Hypothyroidism and hyperthyroidism can overlap with menopause complaints: fatigue, weight change, heat or cold intolerance, palpitations, mood changes, sleep disruption, hair changes, and brain fog. TSH is the usual first blood test, with free T4 added when TSH is abnormal or suspicion is higher.

But routine thyroid screening in asymptomatic adults is not settled. USPSTF concludes that evidence is insufficient to assess the balance of benefits and harms of screening nonpregnant, asymptomatic adults for thyroid dysfunction.

A practical postmenopause approach:

Check TSH when symptoms, family history, autoimmune history, neck findings, medications, atrial rhythm issues, bone loss, or prior abnormal results justify it.
Add free T4 when TSH is abnormal or clinical context demands it.
Consider thyroid antibodies when autoimmune thyroid disease is suspected or prior TSH drift needs context.
Avoid reading thyroid labs without biotin/supplement timing, medication timing, and illness context.

For deeper interpretation, use the TSH normal range by age guide and thyroid function and biological aging.

7. Hormones: what not to turn into a yearly panel

Postmenopause is often where unnecessary testing gets expensive. In most people, yearly FSH, estradiol, progesterone, saliva hormones, and urine hormone metabolites do not clarify healthspan, diagnose postmenopause, or reliably tell you how to dose standard hormone therapy.

ACOG states that data are limited for adjunct hormone tests used to prescribe or dose compounded bioidentical hormone therapy and that these tests are not recommended for those indications. ACOG also notes that most individuals do not require additional ancillary serum testing and that dosing is generally titrated to symptom relief.

That does not mean hormones never matter. It means the question should be specific:

Early menopause or surgical menopause: broader risk review may be appropriate.
Persistent symptoms despite treatment: review route, dose, adherence, contraindications, and alternative causes.
Testosterone therapy discussion: total testosterone, free testosterone or calculated free testosterone, and SHBG may be relevant before and during therapy under clinician guidance.
Unexplained bleeding: this is not a hormone-optimization issue. It needs medical evaluation.

For hormone context, read estrogen and longevity in women, menopause and biological age acceleration, and testosterone in women after 40.

8. Inflammation and advanced markers: useful only with a repeat plan

hs-CRP can be useful in postmenopause because cardiometabolic risk, visceral fat, dental disease, poor sleep, autoimmune conditions, injury, infection, and high training load can all raise inflammatory tone. But hs-CRP is a context marker, not a diagnosis.

If hs-CRP is high once, ask what happened in the prior two weeks:

viral illness, urinary symptoms, dental work, injury, vaccine, flare, or hard training
poor sleep, alcohol, travel, emotional stress, or new medication
high waist circumference, high triglycerides, or worsening glucose markers

Repeat an unexpected high result before using it as a long-term aging signal. The same principle applies to homocysteine, ferritin, B12, vitamin D, omega-3 index, cortisol, IGF-1, or any specialized longevity marker. The more advanced the marker, the more important it is to define the decision before ordering it.

A simple postmenopause annual visit script

Bring a one-page trend sheet instead of a stack of isolated results. Include:

last 3 lipid panels, including ApoB if available
last 3 glucose markers: fasting glucose, HbA1c, and fasting insulin if measured
blood pressure readings, waist circumference, weight trend, and medications
CBC and CMP trend, with dates and notes about illness, training, or fasting
DEXA date and result if done, plus fracture and fall history
symptoms that changed: sleep, hot flashes, vaginal or urinary symptoms, mood, libido, energy, hair, palpitations, dizziness, pain
family history updates: early heart disease, diabetes, osteoporosis, breast cancer, colon cancer, dementia

Then ask:

Which markers are stable enough to repeat less often?
Which abnormal or borderline result should be repeated under controlled conditions?
Which result would change medication, imaging, nutrition, exercise, or referral decisions?
Do I meet criteria for DEXA, diabetes screening, statin-risk discussion, thyroid testing, or additional follow-up?
Is any symptom being blamed on menopause before common non-hormonal causes have been checked?

This is how a checklist becomes care planning instead of data collection.

How SuperAge fits after the blood draw

SuperAge is most useful when you stop reading postmenopause labs in isolation. A rising ApoB, higher HbA1c, lower VO2 max estimate, shorter sleep, higher resting heart rate, increasing waist, and lower activity tell a more actionable story together than any one marker.

Use SuperAge to keep the longitudinal view:

annotate blood draws with illness, travel, alcohol, sleep disruption, medication changes, and training load
compare lab trends with Apple Health metrics such as resting heart rate, HRV, cardio fitness, sleep consistency, activity, and walking patterns
separate one-off lab noise from persistent biological-age signals
decide whether the next action is retesting, lifestyle work, clinical follow-up, or simply more stable measurement conditions

For people tracking both blood work and wearable data, the goal is not to collect more numbers. It is to make the next decision clearer.

FAQ

Do I need yearly estrogen or progesterone tests after menopause?

Usually no. Postmenopause is generally defined clinically after 12 months without a period, and routine sex-hormone testing rarely guides standard care. Testing may be relevant in specific clinical situations, but it should not replace symptom review, risk assessment, and clinician judgment.

What is the most important blood test after menopause?

There is no single best marker. Lipids, glucose markers, CBC, CMP, blood pressure context, bone-risk assessment, and medication review are usually more useful together. If cardiovascular risk is the main concern, ApoB or non-HDL cholesterol can add value beyond a basic lipid panel.

Should vitamin D be checked every year?

Not automatically. Vitamin D testing can be useful with osteoporosis, malabsorption, kidney disease, certain medications, prior deficiency, or other specific risks. Endocrine Society 2024 guidance argues against routine vitamin D testing in generally healthy adults for disease prevention.

Is DEXA a blood test?

No. DEXA is an imaging test for bone density. Blood calcium can be normal even when bone density is low, so calcium does not replace DEXA when fracture risk or age indicates screening.

What labs should I ask for if fatigue started after menopause?

Do not assume fatigue is only hormonal. Discuss CBC, CMP, TSH, ferritin or iron studies, B12, glucose markers, sleep quality, depression or anxiety symptoms, medications, alcohol, pain, activity level, and possible sleep apnea. The exact list depends on your history and exam.

References

American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy.
American Heart Association. Menopause transition and cardiovascular disease risk.
CDC. Testing for cholesterol.
Endocrine Society. Vitamin D for the prevention of disease guideline.
U.S. Preventive Services Task Force. Osteoporosis screening.
U.S. Preventive Services Task Force. Prediabetes and type 2 diabetes screening.
U.S. Preventive Services Task Force. Statin use for primary prevention.
U.S. Preventive Services Task Force. Thyroid dysfunction screening.